WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Announces that YCANTH Receives New Chemical Entity Status
Verrica Pharma Reports Fourth Quarter and Full-Year 2023 Financial Results
WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (œVerrica or œthe Company) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (œVerrica or œthe Company) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Lawsuit alleges false and misleading advertising and promotion of unapproved cantharidin-containing drugs by Dormer Laboratories in violation of federal and state law WEST CHESTER, Pa., Feb. 05,...
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH
Verrica Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315
WEST CHESTER, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (œVerrica or œthe Company) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
WEST CHESTER, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica or the Company) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...